Fenretinide






442 Article(s)
Download
PMID
Title
Journal
Pub. Date
#Total Relationship(s)
1 1305675 Chemotherapy resistant transitional cell carcinoma as a target for chemoprevention. J Cell Biochem Suppl 1992 1
2 1305678 Activity of 4-HPR in superficial bladder cancer using DNA flow cytometry as an intermediate endpoint. J Cell Biochem Suppl 1992 1
3 1306735 Prevention of local relapses and new localisations of oral leukoplakias with the synthetic retinoid fenretinide (4-HPR). Preliminary results. Eur J Cancer B Oral Oncol 1992 Oct 1
4 1386578 In vitro interaction of fenretinide with plasma retinol-binding protein and its functional consequences. FEBS Lett 1992 Aug 10 3
5 1388202 Secretion of vitamin A and retinol-binding protein into plasma is depressed in rats by N-(4-hydroxyphenyl)retinamide (fenretinide). J Nutr 1992 Oct 4
6 1535505 Chemoprevention of breast cancer with retinoids. J Natl Cancer Inst Monogr 1992 1
7 1624219 Potentiation of IL-2-induced t-cell proliferation by retinoids. Int J Immunopharmacol 1992 Feb 2
8 1835622 Long-term tolerability of fenretinide (4-HPR) in breast cancer patients. Eur J Cancer 1991 1
9 2527636 Suppression of rat mammary cancer development by N-(4-hydroxyphenyl)retinamide (4-HPR) following surgical removal of first palpable tumor. Carcinogenesis 1989 Sep 2
10 2643696 Comparative aspects of carotenoids and retinoids as chemopreventive agents for cancer. J Nutr 1989 Jan 1
11 2694156 Chemoprevention of experimental carcinogenesis in animals. Prev Med 1989 Sep 1
12 3621188 Effects of retinoids on metabolizing enzymes and on binding of benzo(a)pyrene to rat tissue DNA. Cancer Res 1987 Oct 1 1
13 7473815 Growth inhibition and induction of apoptosis by fenretinide in small-cell lung cancer cell lines. J Natl Cancer Inst 1995 Nov 15 2
14 7538673 Enhanced expression of an insulin growth factor-like binding protein (mac25) in senescent human mammary epithelial cells and induced expression with retinoic acid. Proc Natl Acad Sci U S A 1995 May 9 1
15 7586155 N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma. Carcinogenesis 1995 Oct 2
16 7586162 N-(4-hydroxyphenyl)retinamide: interactions with retinoid-binding proteins/receptors. Carcinogenesis 1995 Oct 1
17 7654032 In vitro anti-invasive effects of N-(4-hydroxyphenyl)-retinamide on human prostatic adenocarcinoma. Anticancer Res 1995 Jul-Aug 2
18 7685988 N-(4-hydroxyphenyl) retinamide is anticlastogenic in human lymphoblastoid cell lines. Anticancer Res 1993 Mar-Apr 1
19 7744071 Interactions with retinol and retinoids of bovine cellular retinol-binding protein. Eur J Biochem 1995 Apr 15 1
20 7808027 Breast cancer and fenretinide, an analogue of vitamin A. Leukemia 1994 2
21 7961949 Crystallographic studies on complexes between retinoids and plasma retinol-binding protein. J Biol Chem 1994 Nov 25 1
22 8007703 Breast cancer chemoprevention: studies with 4-HPR alone and in combination with tamoxifen using circulating growth factors as potential surrogate endpoints. J Cell Biochem Suppl 1993 1
23 8033144 Effects of N-(4-hydroxyphenyl)retinamide supplementation on vitamin A metabolism. Cancer Res 1994 Aug 1 1
24 8149338 Successful topical treatment of oral lichen planus and leukoplakias with fenretinide (4-HPR). Cancer Lett 1994 Jan 30 1
25 8180126 Down-regulation of retinoic acid receptor beta in mammary carcinoma cell lines and its up-regulation in senescing normal mammary epithelial cells. Cell Growth Differ 1994 Feb 1
26 8208624 N-(4-hydroxyphenyl) retinamide induces cell cycle specific growth inhibition in PC3 cells. Prostate 1994 Jun 1
27 8217599 Retinoids, breast cancer and NK cells. Br J Cancer 1993 Nov 1
28 8221674 Synthetic retinoid fenretinide is effective against a human ovarian carcinoma xenograft and potentiates cisplatin activity. Cancer Res 1993 Nov 15 2
29 8297658 Mammographic patterns in breast cancer chemoprevention with fenretinide (4-HPR). Eur J Cancer 1993 1
30 8319203 Effects of pharmacological retinoids on several vitamin A-metabolizing enzymes. Cancer Res 1993 Jul 1 1
31 8360775 N-(4-hydroxyphenyl)retinamide (fenretinide) induces retinol-binding protein secretion from liver and accumulation in the kidneys in rats. J Nutr 1993 Sep 6
32 8382073 Breast cancer chemoprevention. Eur J Cancer 1993 1
33 8402658 The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients. Cancer Res 1993 Oct 15 4
34 8412202 Fenretinide (4-HPR) in chemoprevention of oral leukoplakia. J Cell Biochem Suppl 1993 2
35 8595390 The synthetic retinoid N-(4-hydroxyphenyl) retinamide (4-HPR) exerts antiproliferative and apoptosis-inducing effects in the androgen-independent human prostatic JCA-1 cells. Biochem Mol Biol Int 1995 Oct 1
36 8621233 Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression. Int J Cancer 1996 Feb 8 1
37 8640761 Comparison of N-(4-hydroxyphenyl)retinamide and all-trans-retinoic acid in the regulation of retinoid receptor-mediated gene expression in human breast cancer cell lines. Cancer Res 1996 Mar 1 1
38 8645719 Retinol-binding protein secretion from the liver of N-(4-hydroxyphenyl) retinamide-treated rats. Biochim Biophys Acta 1996 Jun 4 5
39 8651965 N-[4-hydroxyphenyl] retinamide in rheumatoid arthritis: a pilot study. Arthritis Rheum 1996 Jun 1
40 8687125 Chemopreventive activities of C-glucuronide/glycoside analogs of retinoid-O-glucuronides against breast cancer development and growth. Anticancer Res 1996 Mar-Apr 1
41 8713132 Differential effects of retinoic acid (RA) and N-(4-hydroxyphenyl) retinamide (4-HPR) on cell growth, induction of differentiation, and changes in p34cdc2, Bcl-2, and actin expression in the human promyelocytic HL-60 leukemic cells. Biochem Biophys Res Commun 1996 Jul 25 1
42 8857507 N-(4-hydroxyphenyl)-retinamide increases lecithin:retinol acyltransferase activity in rat liver. J Nutr 1996 Oct 6
43 8948605 Differential effects of retinoic acid and N-(4-hydroxyphenyl)retinamide on head and neck squamous cell carcinoma cells. Laryngoscope 1996 Dec 1
44 8993839 Fenretinide: induction of apoptosis and endogenous transforming growth factor beta in PC-3 prostate cancer cells. Cell Growth Differ 1997 Jan 3
45 9018085 Effects of topical treatment with fenretinide (4-HPR) and plasma vitamin A levels in patients with actinic keratoses. Cancer Lett 1996 Dec 20 2
46 9063520 Chemoprevention of breast cancer with fenretinide (4-HPR): study of long-term visual and ophthalmologic tolerability. Tumori 1996 Sep-Oct 2
47 9125196 N-4-hydroxyphenylretinamide enhances retinoic acid-induced differentiation and retinoylation of proteins in the human acute promyelocytic leukemia cell line, NB4, by a mechanism that may involve inhibition of retinoic acid catabolism. Biochem Biophys Res Commun 1997 Mar 17 1
48 9168437 N-(4-hydroxyphenyl)retinamide induces apoptosis in T lymphoma and T lymphoblastoid leukemia cells. Leuk Lymphoma 1997 Apr 1
49 9316650 Effects of fenretinide (4-HPR) on prostate LNCaP cell growth, apoptosis, and prostate-specific gene expression. Prostate 1997 Oct 1 1
50 9388681 Fenretinide inhibits phorbol ester-induced cyclooxygenase-2 expression in human colon adenocarcinoma cells. Biochem Soc Trans 1997 Aug 1